Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W S El-Deiry

Showing results (1-10 of 102) with videos related to

Pageof 11
Sort By:
Current Opinion in Oncology|January 1, 1997
Role of oncogenes in resistance and killing by cancer therapeutic agentsW S el-Deiry
Current Topics in Microbiology and Immunology|February 28, 1998
p21/p53, cellular growth control and genomic integrityW S el-Deiry
Cell Death and Differentiation|November 1, 2001
Insights into cancer therapeutic design based on p53 and TRAIL receptor signalingW S El-Deiry
Nature Cell Biology|March 7, 2001
Akt takes centre stage in cell-cycle deregulationW S El-Deiry
Seminars in Cancer Biology|April 2, 1999
Regulation of p53 downstream genesW S el-Deiry
Oncogene|March 6, 1997
Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting regionK Somasundaram, W S El-Deiry
Oncogene|April 25, 2000
Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding siteR Takimoto, W S El-Deiry
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2001
DNA replication blockade impairs p53-transactivationR Takimoto, W S El-Deiry
Cell Death and Differentiation|October 28, 2006
p53 downstream target genes and tumor suppression: a classical view in evolutionL M Rozan, W S El-Deiry
International Journal of Cancer|July 29, 1996
In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drugM V Blagosklonny, W S el-Deiry
Pageof 11

Showing results (1-10 of 102) with videos related to

Sort By:
Pageof 11
Current Opinion in Oncology|January 1, 1997
Role of oncogenes in resistance and killing by cancer therapeutic agentsW S el-Deiry
Current Topics in Microbiology and Immunology|February 28, 1998
p21/p53, cellular growth control and genomic integrityW S el-Deiry
Cell Death and Differentiation|November 1, 2001
Insights into cancer therapeutic design based on p53 and TRAIL receptor signalingW S El-Deiry
Nature Cell Biology|March 7, 2001
Akt takes centre stage in cell-cycle deregulationW S El-Deiry
Seminars in Cancer Biology|April 2, 1999
Regulation of p53 downstream genesW S el-Deiry
Oncogene|March 6, 1997
Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting regionK Somasundaram, W S El-Deiry
Oncogene|April 25, 2000
Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding siteR Takimoto, W S El-Deiry
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2001
DNA replication blockade impairs p53-transactivationR Takimoto, W S El-Deiry
Cell Death and Differentiation|October 28, 2006
p53 downstream target genes and tumor suppression: a classical view in evolutionL M Rozan, W S El-Deiry
International Journal of Cancer|July 29, 1996
In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drugM V Blagosklonny, W S el-Deiry
Pageof 11